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Review of Cases of Carcinoid Tumors and Neuroendocrine Carcinoma Diagnosed at Lehigh
Valley Health Network From 2011-2015
Katlyn Mayer and Savitri P. Skandan, MD
Lehigh Valley Health Network, Allentown, Pennsylvania

BACKGROUND / INTRODUCTION

OUTCOMES

• Carcinoid tumors and neuroendocrine carcinomas can
arise in any tissue. Carcinoid tumors are often low grade
in comparison to neuroendocrine carcinomas which
behave like small cell carcinoma of the lung.
• For local/local regional carcinoid or neuroendocrine
carcinoma, surgery is the initial treatment
recommended.
• For stage IV carcinoid tumor, treatment is
recommended if the patient is symptomatic. Octreotide
therapy is recommended for carcinoid syndrome
(diarrhea, facial flushing, and shortness of breath.)
• For stage IV neuroendocrine carcinoma, palliative
chemotherapy is recommended.
• The goals of this study were to determine whether
treatments offered to patients treated at LVHN from
2011-2015 were in compliance with the the National
Comprehensive Cancer Network version 3.2017
(NCCN) Guidelines and to determine the overall survival
of these patients.

Stage II

Stage III

Stage IV

Carcinoid Tumor

95%

96 %

87%

71%

Neuroendocrine
Carcinoma

95%

33%

78%

25%

Table 1. above) Survival of carcinoid tumor and neuroendocrine carcinoma by stage. With the
exception of stage 2 neuroendocrine carcinoma, With the exception of stage II
neuroendocrine carcinoma, these survival rates are similar to the national average.
Figure 3. (left) low
survival rates of
neuroendocrine
carcinoma are attributed
to a small sample size
and mortality from
comorbidities such as
heart disease and stroke.

CONCLUSIONS

METHODS
137 cases of carcinoid tumor
and 99 cases of
neuroendocrine carcinoma
were diagnosed at LVHN
between 2011 and 2015.

Stage I

25 cases were dropped from final
analysis.

Figure 1. (above) Types of treatment received by carcinoid tumor and
neuroendocrine carcinoma patients. Treatments offered by LVHN follow the
NCCN guidelines

One patient was pediatric.
24 cases lacked staging information.

• Treatment offered for carcinoid and neuroendocrine
carcinoma at LVHN followed NCCN guidelines.
• Age of diagnosis ranged from 18-93 years and the
average age of diagnosis was 63.3 years for carcinoid
tumor and 66.7 years for neuroendocrine carcinoma.
• Carcinoid tumors had an overall higher survival rate
than neuroendocrine carcinomas as expected.
• The majority of patients with stages I-III of carcinoid
and neuroendocrine carcinoma actually died of other
causes than their neuroendocrine cancer.
• A higher stage of cancer was correlated to a higher rate
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of mortality for both
tumor types
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123 carcinoid tumors and 89
neuroendocrine carcinomas were
included in the final analysis.
Figure 2. (above) Overall survival of carcinoid tumors and neuroendocrine carcinoma.
Neuroendocrine carcinoma tumors tend to be more aggressive than carcinoid tumors.

Age at the time of diagnosis, cancer
morphology, and overall survival based
on treatment and staging were
analyzed in this study.
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